A global data base has enabled eye experts at Flinders University to determine how vitreoretinal lymphoma first appears, offering vital insights that will help doctors diagnose the disease earlier and improve care for patients around the world.
Their research draws on the International Vitreoretinal BCell Lymphoma Registry, the world’s largest global project dedicated to understanding this aggressive eye cancer.1
Vitreoretinal lymphoma is a rare cancer that begins inside the eye but often looks like a simple eye inflammation, which means many people can be treated for the wrong condition before the cancer is recognised.
the Vitreoretinal BCell Lymphoma Registry collects real-world clinical information from multiple countries using a shared protocol that enables researchers to detect trends that would otherwise go unnoticed
The cancer can cause permanent vision loss and, in many cases, is linked with lymphoma in the brain. Earlier diagnosis helps protect sight, reduces distress for patients, and ensures urgent medical checks for possible brain involvement.
Corresponding author Professor Justine Smith, from Flinders Health and Medical Research Institute Eye and Vision, said the Vitreoretinal BCell Lymphoma Registry collects realworld clinical information from multiple countries using a shared protocol that enables researchers to detect trends that would otherwise go unnoticed.
“Our international registry creates an unprecedented opportunity to study this rare cancer in depth and across continents and provides hope for better understanding, better treatment and better quality of life for people affected,” said Prof Smith.
The study includes 138 newly diagnosed patients from Europe, the Americas, the Western Pacific, and SouthEast Asia. Most patients are in their 60s, although men often develop symptoms at a younger age than women. Close to twothirds of patients have the cancer in both eyes at the time they are diagnosed. For about one in four patients, the cancer is already present in the brain or elsewhere in the body when the eye disease is first found.
“This connection highlights how important coordinated care is for people, because eye findings may be the first sign of a much broader illness,” said Prof Smith.
Doctors typically identify early signs of the cancer through standard eye exams and imaging commonly used in everyday practice. These tests can reveal subtle changes that prompt specialists to investigate further.
“Our registry’s global data helps us understand the early warning signs that doctors should look for, especially when a patient’s symptoms don’t fit the usual pattern,” she said.
The study confirmed that the vast majority of patients have the same type of lymphoma, a finding that has been difficult to establish until now. Additionally, it found that while many still have useful vision when the cancer is found, others are already experiencing serious sight impairment.
Prof Smith said the findings show “how global data collection gives clarity that individual studies cannot provide”.
“Understanding these patterns helps clinicians explain what patients may experience and feeds into decisions about treatment,” she said.
Building Knowledge
Prof Smith said the registry is central to improving outcomes for people affected by this rare disease. And as more centres join the registry, researchers will be able to track how people’s vision changes over time and evaluate which treatments work best for longterm survival. The next stages of research will focus on improving outcomes and supporting people living with this challenging cancer.
The work was supported by the Tour de Cure and the Queensland Eye Institute Foundation, and the National Health and Medical Research Council.
Reference
- International Vitreoretinal B‐Cell Lymphoma Registry Investigator Group. Presenting clinical features of vitreoretinal lymphoma. Clin Exp Ophthalmol. 2026 Mar 1. doi: 10.1111/ceo.70067. Epub ahead of print. PMID: 41764659.
